South Korean implant company DIO partners with Pusan National University Dental Hospital to develop AI dental care platform

Source: Seoul Economic Daily

DentalGoodNews｜On November 11, 2026, Korean digital implantology company DIO Corporation (039840.KQ) (hereinafter referred to as "DIO") announced that it has signed a memorandum of understanding (MOU) with Pusan National University Dental Hospital and the Pusan National University Industry-University Cooperation Foundation to jointly advance the clinical validation and industrialization of an artificial intelligence-driven dental digital transformation (Dental AX) platform.

Under the agreement, Pusan National University Dental Hospital will be responsible for validating the platform's clinical safety and efficacy, and assessing its usability and application potential in real clinical settings. The Pusan National University Industry-University Cooperation Foundation will support joint research, national R&D project planning, and the commercialization of research outcomes.

DIO is responsible for the platform's development, operation, and technical support, and plans to feed clinical validation results and user evaluation feedback into its R&D process for platform upgrades. Meanwhile, the company intends to use the data obtained during the validation process to advance domestic and international Medical Device Registration and approval as well as subsequent commercialization.

The three parties also plan to collaborate on joint research, demonstration projects, professional talent development, and academic and industry exchanges, gradually establishing a collaborative framework covering clinical validation, regulatory approval, joint research, and industrialization.

This collaboration is part of DIO's efforts to advance the development and commercialization of its AI dental digital platform. According to previous DGN reports, on June 30, 2026, DIO signed a strategic MOU with Korean IT services company LG CNS to jointly develop an AI implant surgery design automation system and a cloud-based integrated platform connecting digital workflows such as diagnosis, treatment planning, and restoration.

Source: DIO Corporation

On October 10, 2026, DIO unveiled its AI implant treatment platform "DIO AX" at the DIO International Meeting 2026. The platform integrates clinical data accumulated by DIO through its digital implantology solution DIO NAVI with LG CNS's AI technology, aiming to connect diagnostic data analysis, Implant placement position planning, and restoration design into an integrated workflow. The company also set a goal of achieving KRW 100 billion in direct platform revenue by 2030, a target that excludes indirect revenue from growth in existing product sales.

DIO CEO Kim Jong-won said the company hopes to leverage industry-academia-research-clinical collaboration to validate the clinical reliability and practical application potential of AI digital dental technology, further improve the platform's maturity, and promote its application in global clinical settings.